Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Current Assets (2021 - 2025)

Lyra Therapeutics has reported Current Assets over the past 5 years, most recently at $16.3 million for Q4 2025.

  • Quarterly results put Current Assets at $16.3 million for Q4 2025, down 62.18% from a year ago — trailing twelve months through Dec 2025 was $16.3 million (down 62.18% YoY), and the annual figure for FY2025 was $16.3 million, down 62.18%.
  • Current Assets for Q4 2025 was $16.3 million at Lyra Therapeutics, down from $23.0 million in the prior quarter.
  • Over the last five years, Current Assets for LYRA hit a ceiling of $122.4 million in Q2 2022 and a floor of $16.3 million in Q4 2025.
  • Median Current Assets over the past 5 years was $68.4 million (2021), compared with a mean of $69.8 million.
  • Biggest five-year swings in Current Assets: soared 110.42% in 2022 and later plummeted 62.18% in 2025.
  • Lyra Therapeutics' Current Assets stood at $47.9 million in 2021, then soared by 110.42% to $100.8 million in 2022, then rose by 3.96% to $104.8 million in 2023, then plummeted by 58.95% to $43.0 million in 2024, then plummeted by 62.18% to $16.3 million in 2025.
  • The last three reported values for Current Assets were $16.3 million (Q4 2025), $23.0 million (Q3 2025), and $31.1 million (Q2 2025) per Business Quant data.